Article Text

PDF

PTU-082 Paediatric Inflammatory Bowel Disease Unclassified In Scotland: Incidence And Natural History
  1. FL Cameron1,
  2. P Henderson1,
  3. RK Russell2,
  4. DC Wilson1
  1. 1Child Life and Health, University of Edinburgh, Edinburgh, UK
  2. 2Paediatric Gastroenterology, Royal Hospital for Sick Children, Glasgow, UK

Abstract

Introduction Inflammatory Bowel Disease Unclassified (IBDU) accounts for ~10% of paediatric IBD (PIBD). The natural history of IBDU includes potential evolution to Crohn’s disease (CD) or ulcerative colitis (UC). Few epidemiologically robust studies of IBDU exist so we aimed to describe the incidence and the natural history of paediatric IBDU in a population-based cohort.

Methods Incidence of IBDU was collected over a 10-year period (01/03–12/12) from the two largest Scottish paediatric gastroenterology networks (serving 74.4% of Scottish population <16 years). Demographics, diagnostic investigation and follow-up data were obtained until study end (31.10.13; unless prior transition or emigration) to ascertain reclassification of IBD subtype, clinical progress and outcome at last follow up. Incidence rates and trends were calculated using publicly available population data and statistics generated using Poisson regression.

Results 65 patients were IBDU (57% male) at diagnosis with a median age of 11.3yrs (range 2.6–15.9). The age adjusted incidence of IBDU was 0.65/100,000/yr (95% CI 0.42–0.97) in the 5-year epoch 2003–2007 and 1.14/100,000/yr (95% CI 0.81–1.56) for 2008–2012, a non-significant increase (p = 0.068). All patients had colonoscopy (74% ileal intubation), 62 (95%) had an upper GI endoscopy; remaining 3 had small bowel imaging. 61 (94%) had radiological imaging, 44 (68%) had a barium meal and follow through with 15 (23%) having MR enterography. At diagnosis, 53 (82%) had a pancolitis, 4 (6%) had disease distal to the hepatic flexure, 5 (8%) had disease distal to the splenic flexure and 3 (4%) had proctitis. 37 (57%) had mild disease (defined as mild infrequent relapses) while 7 (11%) had severe chronically active disease with 5 (8%) requiring Infliximab. Median follow-up was 3.1 yrs (range 0.4–6.8). 16 (25%) had their diagnosis changed (all after endoscopic re-evaluation) after a median of 1.6yrs (range 0.6–5.7), to CD in 11 and UC in 5; 10 (15%) remained IBDU. 3 (4%) required surgery and had colectomy and end ileostomy, 2 (66%) had diagnosis changed to UC prior to surgery whilst the other remained IBDU and reclassified to CD later.

Conclusion In the first ever UK population-based epidemiological study of IBDU, the incidence of IBDU demonstrated a non-significant trend to rise during the 10 year study period. 25% of patients had their diagnosis changed after endoscopic re-evaluation, more than previously reported by systematic review (Prenzel and Uhlig JCC 2009) after median follow up of 1.6 years. Most cases had inactive/mild disease activity; a minority remained IBDU despite re-assessment.

Disclosure of Interest None Declared.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.